The drug developer has received the convertible note financing from Eli Lilly as part of a licence and collaboration deal that could reach $190m.
AC Immune, a Switzerland-based company developing drugs for Alzheimer’s disease, has raised $50m in convertible note financing from pharmaceutical firm Eli Lilly as part of a licence and collaboration agreement.
Founded in 2013, AC Immune develops drugs and diagnostic products intended to prevent and treat diseases caused by misfolding proteins.
The company has built two technology platforms to create antibodies, small molecules and vaccines designed to treat diseases caused by the degeneration of the nervous system.
As a result of…
